An experimental Alzheimer’s drug outperforms one just approved by the FDA
(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave
Read More(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave
Read More(By Andrew Joseph for STAT) When the genome-editing tool CRISPR is thought of as a potential medicine, the targets that
Read MoreThe FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the
Read More(By Rylee Wilson for Becker’s Hospital Review) Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease, will
Read More(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following
Read More(By Arthur Allen for KFF Health News) This week the FDA is expected to approve what many scientists and doctors
Read More(By Bari Faye Dean for Becker’s Hospital Review) Older adults with Alzheimer’s disease and related dementia are twice as likely
Read More(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval
Read MoreBy Sara Boden, WESA on June 20, 2023 for Kaiser Family Foundation Angela Reynolds knew her mother’s memory was slipping,
Read MoreBy Jon Hamilton on June 19, 2023 for NPR Diseases like Alzheimer’s, Parkinson’s, and Huntington’s are caused by toxic clumps
Read More